Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HPN 424

Next Previous
Drug Profile

HPN 424

Alternative Names: HPN-424; PSMA/CD3-specific TriTAC

Latest Information Update: 15 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Harpoon Therapeutics
  • Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 11 Mar 2024 Harpoon Therapeutics has been acquired by Merck & Co
  • 27 Feb 2023 Harpoon Therapeutics terminates phase I/II trials in Prostate cancer (Late-stage disease, Hormone refractory, Metastatic disease, Second line therapy or greater) in United Kingdom, USA due to the decision not to proceed with the expansion phase of the study (IV) (NCT03577028)
  • 08 Apr 2022 Pharmacodynamics data from preclinical studies in Prostate cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top